Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071758 | 0.85 | GCK (0.59) | GCKNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13072162 | 0.85 | GCK (0.60) | GCKNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13282846 | 0.83 | NPC1 (0.59) | GCKNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13283042 | 0.83 | NPC1 (0.59) | GCKNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1380947 | 0.82 | GCK (0.69) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL1426945 | 0.82 | GCK (0.82) | GCKKCNH2HRH3CYP1A2ABCB1 | |
| SCHEMBL1378663 | 0.81 | GCK (0.79) | GCKKCNH2CYP1A2ABCB1CYP3A4 | |
| SCHEMBL13072160 | 0.78 | GCK (0.61) | GCKNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13988997 | 0.77 | NPC1 (0.72) | GCKNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1426913 | 0.75 | GCK (0.82) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885NPC1 2655/4885ALDH1A1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.